ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for the MULTIDISCIPLINARY CANCER CARE TEAM and the PATIENTS they serve since 1997
Meetings & Education
Financial Advocacy & Patient Assistance
SCOS Fellows Travel Award
Patient Advocacy Organizations
State & Federal Resources
Off-Label Use Literature
Find A Clinical Trial
National Professional Organizations
SCOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Pembrolizumab for Advanced Cervical Cancer
On June 12, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck and Co. Inc.) for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
Read the full FDA press release here.
Tweets by OSSatACCC